MINNEAPOLIS--(BUSINESS WIRE)--Marking a major milestone toward expanding the use and utility of minimally invasive endovascular procedures, Medtronic, Inc. (NYSE: MDT), today announced the enrollment of the first patient in the Medtronic Dissection Trial, which is evaluating the clinical performance of the Valiant Thoracic Stent Graft with the Captivia Delivery System for the treatment of acute, complicated Type B aortic dissection – a serious cardiovascular condition associated with high morbidity and mortality. The study is being conducted under an Investigational Device Exemption (IDE) in the United States.
